Intelligence / Healthtech / New Clinical Trials / Cutempa Medical AG
Clinicaltrial registered13 Nov 2026
Cutempa Medical AG
13 Nov 2026: Trial registered · Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot Wounds. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 13 Nov 2026
- Title
- Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot Wounds
- Conditions
- Diabetic Foot Disease, Foot Ulcer Due to Type 1 Diabetes Mellitus, Foot Ulcer Due to Type 2 Diabetes Mellitus
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Germany
- Country
- Germany
- Reference
- NCT07937215
- Location
- Germany
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Cutempa Medical AG
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Germany
New Clinical Trials
18 NovDiabetes Free, Inc.trial registered · Dual-targeting of B & T Cell Pathways Evaluation TrialClinical18 NovGaia AGtrial registered · Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause SymptomsClinical16 NovBoehringer Ingelheimtrial registered · A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or ObesityClinical16 NovFinzelberg GmbH & Co. KGtrial registered · Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy AdultsClinical12 NovAponia Laboratories, Inc.trial registered · Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue ContusionsClinical12 NovMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germanytrial registered · Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe EczemaClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.